Moore Capital Management, LP Brainstorm Cell Therapeutics Inc. Transaction History
Moore Capital Management, LP
- $4.85 Billion
- Q3 2024
A detailed history of Moore Capital Management, LP transactions in Brainstorm Cell Therapeutics Inc. stock. As of the latest transaction made, Moore Capital Management, LP holds 200,000 shares of BCLI stock, worth $455,999. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200,000Holding current value
$455,999% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding BCLI
# of Institutions
41Shares Held
10.8MCall Options Held
160KPut Options Held
30.5K-
Armistice Capital, LLC New York, NY6.9MShares$15.7 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.51MShares$3.44 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA683KShares$1.56 Million0.0% of portfolio
-
Black Rock Inc. New York, NY386KShares$881,0230.0% of portfolio
-
Liberty Wealth Management LLC Oakland, CA340KShares$775,5410.01% of portfolio
About BRAINSTORM CELL THERAPEUTICS INC.
- Ticker BCLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,486,200
- Market Cap $83.2M
- Description
- Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...